Successful immunization of naturally reared pigs against porcine cysticercosis with a recombinant oncosphere antigen vaccine  by Jayashi, César M. et al.
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Taenia  solium  causes  cysticercosis  in  pigs  and  taeniasis  and  neurocysticercosis  in  humans.
Oncosphere  antigens  have  proven  to  be effective  as  vaccines  to protect  pigs  against  an
experimental  infection  with  T.  solium.  A pair-matched  vaccination  trial  ﬁeld,  using  a  com-
bination  of  two  recombinant  antigens,  TSOL16  and  TSOL18,  was  undertaken  in  rural  villages
of Peru  to evaluate  the  efﬁcacy  of this  vaccine  under  natural  conditions.  Pairs  of  pigs  (n  = 137)
comprising  one  vaccinated  and  one control  animal,  were  allocated  to  local  villagers.  Animals
received  two  vaccinations  with  200  g of each  of TSOL16  and  TSOL18,  plus  5 mg Quil-A.
Necropsies  were  performed  7  months  after the  animals  were  distributed  to  the farmers.aeniasis
SOL16
SOL18
accine
mmunization
igs
Vaccination  reduced  99.7%  and  99.9%  (p <  0.01)  the  total  number  of  cysts  and  the number  of
viable cysts,  respectively.  Immunization  with  the  TSOL16–TSOL18  vaccines  has  the  poten-
tial to  control  T.  solium  transmission  in  areas  where  the  disease  is  endemic,  reducing  the
source for  tapeworm  infections  in  humans.
© 2012 Elsevier B.V. Open access under CC BY license.
ield trial
. Introduction
Taenia solium is a taeniid cestode parasite which causes
aeniasis in humans and cysticercosis in humans and pigs.
hen the cysticerci affect the central nervous system the
isease is called neurocysticercosis. Neurocysticercosis is
 zoonotic disease which is widespread in the developing
orld. In Latin America there are more than 400,000 symp-
omatic neurocysticercosis cases with almost 10% of these
ases occurring in Peru (Bern et al., 1999). The life cycle of
. solium involves both humans and pigs. The adult tape-
orm lives in the human small intestine. Tapeworm eggs
re shed in the feces and if ingested by a pig, the larvae
r cysticerci develop principally in the muscle of the pig.
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Open access under CC BY license.Humans become infected with the adult tapeworm after
ingesting raw or incompletely cooked pork meat infected
with the larval stage (cysticercus). However, the patholog-
ical consequences of T. solium infection in humans arise
because humans may  also become accidental intermediate
hosts because of ingestion of tapeworm eggs. In humans
the eggs develop into larval cysts that are mainly located
in the muscular and nervous tissues. The clinical signiﬁ-
cance of the parasite occurs particularly when cysts that are
located in the central nervous system cause serious neu-
rological disorders such as seizures and epilepsy (Schantz
et al., 1993; Garcia and Del Brutto, 2005).
Logically, T. solium control could be achieved by
improvements in public sanitation (through health educa-
tion), treatment of humans to remove the adult tapeworms,
preventing pigs having access to human faces, inspection of
pork meat to prevent infected material being available for
consumption, or by killing the cysticerci in the intermedi-
ate host with anthelmintics (Garcia and Del Brutto, 2005;
ry Paras262 C.M. Jayashi et al. / Veterina
Gonzalez et al., 2001; Pawlowski et al., 2005; Sarti et al.,
2000). Despite the availability of these potentially effective
methods to interrupt the parasite’s life cycle, cysticercosis
and neurocysticercosis remain serious problems in many
developing countries (Garcia and Del Brutto, 2005).
A potential method for controlling T. solium transmis-
sion is the use of vaccination in pigs (Cai et al., 2008;
Flisser et al., 2004; Gonzalez et al., 2005; Lightowlers, 1999,
2010; Sciutto et al., 1990). Using an effective vaccine in
pigs would remove the source of tapeworm infection in
humans, breaking the parasite’s life cycle and indirectly
eliminating the causative agent of human neurocysticer-
cosis (Lightowlers, 1999, 2010). Oncosphere antigens have
been found to be highly effective as vaccines for preven-
tion of infections with parasites that are closely related to
T. solium such as Taenia ovis (Johnson et al., 1989), Tae-
nia saginata (Lightowlers et al., 1996b)  and Echinococcus
granulosus (Lightowlers et al., 1996a). T. solium homologs
of protective antigens for the other taneiid species have
been identiﬁed and the recombinant proteins expressed
in Escherichia coli. These antigens (TSOL16, TSOL18 and
TSOL45) have been produced as glutathione-S-transferase
(GST) fusion proteins. TSOL18 and TSOL45 have shown high
efﬁcacy as vaccines in preventing pig infections with T.
solium in experimental trials in Mexico, Cameroon, Peru
and Honduras (Flisser et al., 2004; Gonzalez et al., 2005;
Lightowlers, 2006). In a recent vaccination study, the use of
TSOL18 plus oxfendazole prevented any detectable infec-
tion with T. solium in pigs raised under natural conditions
(Assana et al., 2010). The TSOL18 gene is highly conserved
in isolates of T. solium from various geographical locations
of the world (Gauci et al., 2006). However, concerns remain
about how genetic variability may  affect the effectiveness
of the vaccine in control programs. The third oncosphere
antigen, TSOL16, has also been demonstrated to be effective
against experimental challenge with T. solium eggs (Gauci
et al., in press). The availability of multiple protective anti-
gens allowed the possibility of utilizing more than one
antigen in a T. solium vaccine, potentially reducing the like-
lihood of selection for resistant genotypes during practical
application of the vaccine. Here we provide data obtained
from a ﬁeld trial using a combination of the TSOL16 and
TSOL18 antigens in naturally reared pigs in a region of Peru
where T. solium cysticercosis is endemic.
2. Materials and methods
2.1. Study design
This was a pair-matched vaccination trial to assess the
effectiveness of vaccination to prevent porcine cysticerco-
sis infection in naturally reared pigs.
2.2. Animals
The number of animals required for the ﬁeld trial was
calculated using Fisher’s exact test, taking into consider-
ation the prevalence of porcine cysticercosis in the study
area being 10%; a 90% reduction in the occurrence of the
disease in the pigs vaccinated with the TSOL16–TSOL18
vaccine; a power of 80% and a signiﬁcance level of 95%. Onitology 188 (2012) 261– 267
this basis, a minimum of 100 pairs of pigs were required
for the study. The number of animals used in the study
exceeded this minimum requirement, with a total of 274
animals being delivered in pairs to 86 households. Piglets
ranging from 8 to 16 weeks were sourced from farms within
the department of Piura, Peru. Pigs were “criollo” pigs or
“criollo” crosses with several pig breeds (Landrace, Hamp-
shire, Duroc, Poland China, Pietrain). Tongue inspection
was  performed as a screening test to avoid purchasing
infected animals. None of the examined animals were pos-
itive to tongue inspection.
2.3. Study area
Morropon is one of the 10 districts of the province of
Morropon, Piura, Peru. It is located in Northeast Peru, 82 km
from Piura, the closest major city. It has a population of
16,510 inhabitants. The altitude is 131 m above sea level
and geographic coordinates are 5◦10′57′′ south latitude and
79◦58′00′′ west longitude. The climate is dry and hot during
most of the year. Commonly, pigs are raised free roaming
and if not, very rudimentary pig-pens are used to enclose
them.
2.4. Recombinant antigen and vaccine preparation
The cDNA of TSOL16 (Gauci and Lightowlers, 2003)
and TSOL18 (Gauci et al., 1998) were cloned into pGE
(GE Healthcare), and expressed as GST fusion proteins in
E. coli, as described by Flisser et al. (2004) and Gauci et al.
(in press).  One dose of vaccine consisted of 200 g each
of TSOL16-GST and TSOL18-GST plus 5 mg  Quil-A (Bren-
ntag Biosector, Frederikssund, Denmark). The TSOL16 and
TSOL18 puriﬁed protein elutions were sterilized by ﬁltra-
tion through a 0.22 m membrane ﬁlter prior to use. Quil-A
solution was prepared in PBS and sterilized by ﬁltration
through a 0.22 m membrane ﬁlter. Quil-A was added to
an equivalent of 5 mg  per dose, Tris buffer at 50 mM was
added to 100% ﬁnal volume and the vaccine lyophilized and
stored at 4–10 ◦C in vials of 10 and 25 doses. Vaccine was
rehydrated immediately before use using sterile distilled
water.
2.5. Vaccination scheme
Animals were randomly assigned to the treatment (vac-
cinated) and control groups. Piglets in the treatment group
were vaccinated intramuscularly in the neck with a dose of
the TSOL16–TSOL18 vaccine per animal and Classical Swine
Fever (CSF) vaccine (Pest-Vac, Fort Dodge-Wyath) at day 1,
in separate injection sites. Identical booster vaccinations
with TSOL16–TSOL18 and the CSF vaccines into their same
respective vaccine sites, occurred four weeks after the ﬁrst
vaccination.
Piglets in the control group were vaccinated intramus-
cularly only with the CSF vaccine and given an identical
booster vaccination four weeks after ﬁrst vaccination. To
reduce the likelihood of a CSF outbreak in our study houses,
all other pigs from the household were vaccinated against
CSF.
ry Parasitology 188 (2012) 261– 267 263
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Table 1
Incidence of infection, viable, degenerated and total cyst counts by treat-
ment group in the ﬁeld vaccination trial, Peru.
Findings Control Vaccinated
Assessed by necropsy 107 113
Infected 18 7
Cumulative incidence 16.80% 6.20%
Infected with viable cysts 15 2
Infected with viable muscle cysts 15 1
Incidence of pigs with viable muscle cysts 14.02% 0.88%
Total cysts 34,081a 83
Viable cysts 33,416a 3
Viable muscle cysts 33,333a 1
Degenerated 665 80
Range of cyst countsb 1–18,598 1–54
Meanb 1893.9 11.9
Medianb 63.5 6
Degenerated/viable 665/33,416 80/3
Degenerated/viable ratio 0.02a 26.67
a Signiﬁcantly different from the vaccinated group (Wilcoxon signed-C.M. Jayashi et al. / Veterina
.6. Management of the animals
All pigs were purchased, acclimatized for a period of 48 h
nd then vaccinated according to the vaccination scheme.
his period was used to monitor for the appearance of any
etrimental health condition and treat it before giving the
igs to their new owners. Piglets were distributed to the
ecipient households as pairs of sentinel pigs, consisting
f one vaccinated and one control animal. Animals were
ought and delivered in four lots, delivering the ﬁrst group
n January–February 2009 (74 animals), second in March
009 (42 animals), third in June 2009 (58 animals) and the
ast group in October 2009 (100 animals).
.7. Household selection criteria and delivery
Properties where the trial animals were to be hosted
ere selected following various criteria. In the ﬁrst cri-
erion, selected properties where at least one pig which
cored strongly positive (to ≥4 bands) in the Electro-
mmunotransfer-Blot (EITB) assay for porcine cysticercosis.
hese data had been determined three months earlier
uring a sero-epidemiological survey of the villages. The
econd criterion was to deliver piglets to neighboring
ouseholds within a 50-m radius from the households
t which a strongly serologically positive pig had been
etected. The ﬁnding of a strongly serologically positive pig
or T. solium cysticercosis would suggest the likelihood of T.
olium transmission either at this property or in the imme-
iate vicinity (Lescano et al., 2007). The household owners
id not know the animals belonged to any speciﬁc treat-
ent group. To avoid any alteration of the natural feeding
ehavior of pig in the ﬁeld, owners were instructed to raise
he pigs according to their usual practices.
.8. Transport to a cysticercosis low-risk area
After the animals had remained at their host properties
or approximately 4 months, the animals were transported
o a facility that was considered to be a very low risk for
urther exposure of the animals to T. solium.  This facility
as the Cysticercosis Working Group in Peru (CWGP) rural
ampus located in Tumbes, Peru. Animals stayed in pens
ocated inside the campus for 10–12 weeks providing suf-
cient time to allow any T. solium infections that had been
cquired by the animals immediately before the comple-
ion of the ﬁeld exposure period, enough time to develop
nto detectable cysticerci.
.9. Necropsy
Necropsies were performed 7 months after the ﬁrst
accination to determine the incidence of the disease
nd intensity of infection. The viability of cysticerci was
ssessed on the infected animals. Personnel carrying out
he necropsies and cyst counting did not know the group
o which the individual animals belonged. Animals were
uthanized following the ethics policies and proceedings
uthorized by the Universidad Nacional Mayor de San Mar-
os, Lima, Peru. Muscles were sliced with sagittal cuts,
ndeavoring not to exceed 3 mm between cuts. Cysts wererank test p < 0.01).
b The range, mean and median were calculated based on the total cysts
counts of the infected animals.
classiﬁed into healthy and degenerated cysts. Healthy cysts
were translucent vesicles ﬁlled with transparent ﬂuid of
variable size from 5 to 15 mm in diameter with an oval
or round shape. Inside the healthy cysts a visible white
scolex could be found. Degenerated cysts were small vesi-
cles that varied from whitish to yellowish color and had a
dense ﬂuid. As a general characteristic, degenerated cysts
were smaller than the healthy cyst and had the appearance
similar to that of a grain of rice.
2.10. Statistical analysis
Comparisons between the incidence of infection in the
pairs of animals from the vaccinated and control groups
were calculated by the McNemar-chi2 test (95% signiﬁ-
cance level). Comparison of the cyst counts per group was
calculated by the Wilcoxon signed-rank test (95% signiﬁ-
cance level). Fisher’s exact test was  used to compare the
degenerated:viable cyst ratios of the control and vacci-
nated group. The adjusted relative risk, 95% conﬁdence
intervals and p values of acquiring the disease during
their time of exposure were calculated using a multivari-
ate Poisson regression. Odds ratios (OR) were calculated
to compare the number of cysts in each anatomical region
between the vaccinated and control groups.
3. Results
From the 274 animals involved in the trial, 220 were
included in the necropsies. Pigs not assessed by necropsy
examination either died or were lost during the trial. The 54
lost animals represented 19.7% (54/274) of the total num-
ber of pigs delivered. From the 220 euthanized pigs, 113
animals belonged to the treatment group and 107 to the
control group.A summary of the incidence, total, viable and degen-
erated cyst counts, as well as the viable/degenerated
ratio of both groups is shown in Table 1. Numerous cys-
ticerci were found in the 18 infected control animals
ry Parasitology 188 (2012) 261– 267
Table 2
Number of positive and negative pairs of pigs determined by necropsy per
treatment group in the ﬁeld vaccination trial, Peru.
Group Vaccinated Total
Positive Negative Unknown
Control
Positive 4 13 1 18a
Negative 3 80 8 91
Unknownb 0 11 17 28
Total 7 104 26 137
a Signiﬁcant difference between the infected control pairs of animals
and  vaccinated ones (McNemar-chi2 test, p < 0.05).
b Those animals for which data were available only from 1 member of a264 C.M. Jayashi et al. / Veterina
(prevalence = 16.8%, total number of cysticerci = 34,081,
mean = 1893.4, median = 63.5, range = 1–18,451). From the
113 animals vaccinated with the TSOL16–TSOL18 vaccine,
93.8% (106/113) pigs were free of infection. There was
a signiﬁcant 99.7% reduction (Wilcoxon signed-rank test,
p < 0.01) in the total number of cysts in the vaccinated group
(Total number of cysticerci = 83, mean = 11.9, median = 6,
range = 1–54).
The degenerated cysts found in the controls represented
2.0% (665/34,081) of the group’s total cyst count, whereas
the degenerated cysts in the vaccinated group represented
96.4% (80/83) of the group’s total cyst count. There was
a signiﬁcant 99.9% (Wilcoxon signed-rank test, p < 0.01)
reduction in the number of viable cysts in the vaccinated
group (viable cysts = 3, mean = 1.5) versus the animals in
the control group (viable cysts = 33,416, mean = 2227.7).
In the control animals, for every 50 viable cyst 1 degen-
erated cyst was found (degenerated:viable ratio = 0.02
[665/33,416]). On the other hand, in the vaccinated
group, for every viable cyst 27 degenerated cysts were
found (degenerated:viable ratio = 26.67 [83/3]). These
viable/degenerated ratios were signiﬁcantly different
(Fisher’s exact test p < 0.001).
The number of infected pairs by group is shown in
Table 2. The infected animals belonged to 20 pairs. There
were 19 out of the 20 positive pairs that had their match-
ing pair for the necropsy examination, and 17 pairs (from
the 137 starting pairs) where both pigs were unavailable to
assess their infection status because they either died or oth-
erwise lost during the experiment. There was a signiﬁcant
difference between the incidence of infection in the treat-
ment and control groups when analyzing the pairs of pigs
(McNemar-chi2 test, p < 0.05). Using a multivariate analysis
and adjusting the regression by village, house and sex, the
risk of ﬁnding an animal with viable cysts and with muscle
Table 3
Viable and degenerated cyst counts in the pairs of pigs that were infected as dete
Pair number Cyst count, TSOL16–TSOL18 group 
Viable Degenerated Tota
12 0 0 0 
20  1a 5 6 
23  0 0 0 
25  0 0 0 
39 0  0 0 
45  0 0 0 
46  0 0 0 
47c – – – 
51  0 10 10 
56  0 0 0 
57  0 0 0 
73  0 54 54 
84  0 0 0 
86  0 0 0 
91  0 1 1 
98  0 0 0 
102  0 0 0 
113  2b 5 7 
120  0 1 1 
122  0 4 4 
a The viable cyst was found in the muscle.
b The two viable cysts were found in the brain.
c The vaccinated animal was lost during the experiment and unavailable for nepair are shown as individual animals, with the associated pair indicated as
unknown. Pairs in which both animals were unavailable for examination
are  indicated as unknown/unknown.
viable cysts was  11.53 (95% CI 1.73–21.34) and 12.61 (95%
CI 2.79–22.45) times more in the control than the vacci-
nated group, respectively.
A summary of the cyst counts in the infected animals
per group is given in Table 3. From seven infected ani-
mals in the vaccinated group, ﬁve had degenerated cysts
and two  animals had viable cysticerci. From these two ani-
mals, one had two viable cysts in the brain only and the
other had one viable muscle cyst. Localization of cysts in
both groups had a similar pattern, 53.0% (vaccinated) and
54.3% (control) of the cysts were localized in the limbs,
while the remaining cysts found in the tongue and the
heart as well as spinal, intercostal and head muscles. Ani-
mals in the control group with a parasite burden >1084
cysts, had cysts in skeletal muscle, cardiac muscle and
brain parenchyma. Brain cysts were found in 38.9% (7/18)
of the infected controls. The animals in the control group
had statistically signiﬁcantly lower odds to have cysts in
the head muscles (OR = 2.73 [1.26–5.93]), tongue (OR = 8.03
rmined by necropsy in the ﬁeld vaccination trial, Peru.
Cyst count, control group
l Viable Degenerated Total
3271 203 3474
0 7 7
987 26 1013
4 0 4
74 1 75
1 0 1
0 5 5
1 0 1
0 0 0
49 3 52
8172 77 8249
0 0 0
1010 75 1085
1 0 1
0 200 200
18,573 25 18,598
1053 31 1084
16 11 27
36 1 37
168 0 168
cropsy.
C.M. Jayashi et al. / Veterinary Parasitology 188 (2012) 261– 267 265
Table 4
Anatomical distribution of the cysts in the animal carcasses per treatment group in the ﬁeld vaccination trial, Peru.
Anatomical region Control Vaccinated
Viable Degenerated (%)a Viable Degenerated (%)a
Right forelimb 4934 105 14.79 0 6 7.23
Left  forelimb 4480 62 13.33 0 15 18.07
Right  ﬂank 2467 25 7.31 0 1 1.20
Left  ﬂank 2585 37 7.69 0 6 7.23
Brainb 83 9 0.27 2 0 2.41
Heart 472 24 1.46 0 2 2.41
Cervical-thoracic vertebrae 3713 65 11.09 0 11 13.25
Tongueb 525 99 1.83 0 11 13.25
Head  musclesb 822 61 2.59 0 6 7.23
Right  hind limb 4506 60 13.40 0 10 12.05
Left  hind limb 4213 86 12.61 1 12 15.66
Sacrum 4616 32 13.64 0 0 0
Total  33,416 665 3 80
a Proportion of the total cyst count.
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tb Animals in the control group had a signiﬁcantly lower odds to have c
4.24–15.22]) and brain (OR = 8.94 [2.17–36.92]). A dis-
ribution of the anatomical location of cysts is shown in
able 4.
. Discussion
This study reinforces the high efﬁcacy of the onco-
phere antigen vaccine against porcine cysticercosis and
he potential for use of the vaccine in programs to control
eurocysticercosis. The effectiveness of vaccination (>99%)
eported in this trial is as high as the vaccine effectiveness
ound in studies that used controlled conditions (Flisser
t al., 2004; Gonzalez et al., 2005). Under natural conditions
he effectiveness of the TSOL16–TSOL18 vaccine for the
ontrol of porcine cysticercosis in Peru was similar to that
escribed for use of TSOL18 as a vaccine in the experiment
ndertaken by Assana et al. (2010) in Cameroon. However,
here are some differences between the trial in Peru and
he trial undertaken in Cameroon. In Peru the effectiveness
f vaccination alone was assessed without the incorpora-
ion of an oxfendazole treatment in the trial animals, as
as undertaken in Cameroon. Furthermore, the Peruvian
rial incorporated a second recombinant antigen in the vac-
ine (TSOL16), whereas in Cameroon only TSOL18 was  used
lone. Despite the differences, both trials achieved a >99%
eduction in the total number of cysts as well as the number
f viable cysts in vaccinated animals.
Animals in the control group of our study had more
han 12 times the risk of having a viable cyst compared
o the animals in the vaccinated group. Viable cysts are the
nly ones that could have developed into the adult para-
ite. Although the three viable cysts (two in brain and one
n muscle) found in the vaccinated animals had the poten-
ial to develop into adult tapeworms, only the one viable
uscle cyst would have been likely to perpetuate the life
ycle because the consumption of the brain is a rare practice
mong the rural villagers (Gonzalez et al., 1998).
The TSOL antigens are expressed exclusively in the
ncosphere (Gauci et al., 1998) and for this reason vaccina-
ion with these antigens would not be expected to have anyis anatomical site.
effect on established cysticerci. Nevertheless, there is some
evidence in this ﬁeld vaccination trial, which suggests that
protection provided by the TSOL16 and TSOL18 antigens
led to an increase in the number of non-viable cysticerci
in the vaccinated animals. Previous studies in T. solium and
Taenia taeniaeformis have reported similar ﬁndings. Vac-
cination with S3Pvac vaccine (a Taenia crassiceps-based
synthetic peptide vaccine) against T. solium cysticerco-
sis, found that cysticerci were susceptible to the immune
responses induced by the vaccine (de Aluja et al., 1999).
The higher ratio of degenerated cysts observed in the vac-
cinated group of our study, resembles a pattern similar to
Bøgh et al. (1988) and Rajasekariah et al. (1980) ﬁndings in
T. taeniaeformis,  with an increased number of degenerated
cysts. Other evidence relating to the factors which affect the
viability of a muscle lesion caused by T. solium in pigs is that
animals infected with T. solium eggs and then re-infected
130 days later shown an almost 1:1 ratio of degenerated
and viable cysts (de Aluja et al., 1996, 1999). Overall in
our study, degenerated cysts represented 96.5% of the total
cyst count in the vaccinated group versus 2% in the control
group. Future research could assess the potential cysticidal
effect of the TSOL16–TSOL18 vaccines.
The precise duration of immunity conferred by vacci-
nation with TSOL antigens is unknown. In both the study
detailed in this paper and the trial described by Assana et al.
(2010),  the vaccine was  effective in achieving high levels of
protection that were assessed at the times necropsies were
undertaken at the conclusion of the trials. In our study in
Peru, this was  7 months after the initial immunizations. In
the case of the trial undertaken using TSOL18 in Cameroon,
protection was  maintained for at least 10 months after the
ﬁrst immunization (Assana et al., 2010).
This study has some limitations. Despite the precau-
tions taken in selecting the pigs for the vaccination trial,
the infection seen in the animals could not unequivocally
be determined as having been acquired while the animals
were at the villages of Morropon. Animals may  have been
infected before being distributed to the households. Indeed,
serological investigations undertaken after the completion
ry Paras266 C.M. Jayashi et al. / Veterina
of the trial indicated that some of the animals may  have
been infected with T. solium at the time they were initially
distributed to the householders. Hence, the lesions seen in
the vaccinated group cannot be regarded unequivocally as
vaccine failures.
4.1. Pig vaccination in control programs
In establishing a control program for T. solium,  care
would need to be taken in relation to the endemic sta-
bility of disease in pigs. As is known to be the situation
for other taeniid cestode species (Gemmell, 1990), it could
be anticipated that areas where T. solium cysticercosis
was hyper-endemic would exhibit endemic stability with
respect to infection levels in pigs. Disturbance of this sta-
bility by reduction in the prevalence of infected deﬁnitive
hosts could reduce the incidence if infection in pigs, leav-
ing many highly susceptible to any future exposure to
the parasite. This situation is believed to have led to the
occurrence of “cysticercosis storms” in New Zealand where
disturbance of endemic stability of T. ovis in sheep led
to massive infections in ﬂocks that were exposed to T.
ovis eggs (Gemmell, 1978) and is a well understood phe-
nomenon in relation to other infectious diseases (Coleman
et al., 2001). Most of the interventions that have been tested
for T. solium to date have relied on the treatment of the
deﬁnitive hosts (humans) to remove tapeworm infections
(Lightowlers, 2010) and this may  have increased the overall
susceptibility of the pig population to cysticercosis. Indeed
one study found an increase in the prevalence of porcine
cysticercosis after mass treatment of the human population
with a taeniacide (Keilbach et al., 1989). A major advan-
tage of the incorporation of pig vaccination into control
efforts for T. solium would be the replacement of naturally
acquired immunity in the intermediate host population
with vaccine-induced immunity. In this way, the control
efforts would not be readily disrupted should new cases of
taeniasis be introduced into a control region either through
incomplete effectiveness of the control measures or immi-
gration of tapeworm carriers into the control area.
In regions where T. solium was highly prevalent, young
pigs would be born into a contaminated environment and
may  be exposed to T. solium infection prior to them being
vaccinated. It remains unclear whether the TSOL18 has any
effect on established cysticerci, notwithstanding the pre-
ponderance of non-viable lesions in the vaccinated animals
in the ﬁeld trial described here. For this reason, it would be
valuable in a control program to incorporate a measure to
ensure that any viable parasites that were already estab-
lished in animals prior to vaccination were removed as
potential sources for transmission of taeniasis to humans.
Data are not available about the potential for passive trans-
fer of immunity from dams vaccinated with TSOL antigens
to neonates. However, perhaps the simplest method by
which pre-natal or neonatal infections with T. solium could
be eliminated as a potential source of transmission of the
parasite could be achieved by inclusion of a single treat-
ment of piglets with oxfendazole at the same time as the
animals were vaccinated, as was the case in the trial under-
taken in Cameroon (Assana et al., 2010).itology 188 (2012) 261– 267
5. Conclusion
The results obtained by this study reinforce the role of
vaccination as a valuable tool to prevent porcine cysticer-
cosis in areas where the disease is endemic, reducing the
source of infection in humans and indirectly decreasing
the occurrence of neurocysticercosis. With this knowledge,
further studies are necessary to assess the feasibility and
efﬁcacy of control programs that include vaccination under
ﬁeld conditions.
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